Welcome to the e-CCO Library Archive!

Filter:

P411

Four-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patients

Authors:

C. Cassieri*1, R. Pica1, E. v. V. Avallone1, G. Brandimarte2, M. Zippi1, P. Crispino1, G. Lecca2, C. Corrado1, P. Vernia1, P. Paoluzi1, E. v. S. Corazziari1

1 ‘Sapienza’ University, Internal Medicine and Medical Specialties, Rome, Italy, 2’Cristo Re’ Hospital, Internal Medicine, Rome, Italy

P412

Evolution of patients with ulcerative colitis who withdraw the maintenance treatment with mesalazine

Authors:

A. Algaba*, I. Guerra, D. Bonillo, M. Hernández, A. Granja, P. Bernal, F. Berrmejo

Hospital Universitario de Fuenlabrada, Gastroenterology, Madrid, Spain

P413

Endoscopic balloon dilatation of Crohn’s strictures is safe and effective in selected cases

Authors:

A. Asairinachan*, V. An, E. Daniel, M. Johnston, J. Keck, P. Salama, R. Woods

St Vincent’s Hospital Melbourne, Victoria, Australia

Abstract has been withdrawn.

P414

Usefulness of ultrasonography in the assessment of postoperative recurrence of Crohn’s disease

Authors:

M. Murakami*1, T. Kanemura1, A. Haga1, R. Kubota1, K. Yaguchi1, M. Nishio1, S. Tsuda1, T. Ogashiwa1, Y. Kogure1, K. Kasahara1, K. Hirai2, Y. Fukuno2, M. Jin2, A. Hanzawa2, H. Yonezawa2, K. Sakamaki3, K. Numata4, H. Kimura1, R. Kunisaki1

1Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan, 2Yokohama City University Medical Centre, Department of Laboratory Medicine and Clinical Investigation, Yokohama, Japan, 3Graduate School of Medicine, Yokohama City University, Department of Biostatistics and Epidemiology, Yokohama, Japan, 4Yokohama City University Medical centre, Gastroenterology Centre, Yokohama, Japan

P415

Therapeutic drug monitoring of thiopurines in the management of Asian patients with inflammatory bowel disease

Authors:

S. N. W. Chuah*1, P. Delord2, N. Sutiman3, W. F. Leong3, S. C. Kong1, B. Schwender1, P. W. Chan1, H. H. Shim1, E. Salazar1, E. H. Ong4, H. Y. Aw5, J. L. Hartono4, W. C. Lim6, C. Ong7, P. L. Ong8, K. L. Ling1, B. Chowbay2

1Singapore General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 2National Cancer Centre, Clinical Pharmacology Laboratory, Singapore, Singapore, 3Singapore Health Services, Clinical Pharmacology, Singapore, Singapore, 4National University Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 5National University Hospital, Division of Paediatric Gastroenterology, Singapore, Singapore, 6Tan Tock Seng Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 7KK Women’s and Children’s Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 8Changi General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore

P416

An online educational portal is effective in improving knowledge regarding reproduction and IBD

Authors:

K. Wierstra1, K. Smith1, J. Bal2, L. Ambrosio2, K. I. Kroeker2, L. Dieleman2, B. Halloran2, R. N. Fedorak2, K.-A. Berga3, V. W. Huang*4

1University of Alberta, Edmonton, Canada, 2University of Alberta, Gastroenterology, Edmonton, Canada, 3MacEwan University, Edmonton, Canada, 4University of Alberta, Medicine, Edmonton, Canada

P417

Ulcerative colitis: let’s talk about extent

Authors:

A. Vaz*, M. Eusébio, A. Antunes, P. Queirós, T. Gago, T. Belo, P. Caldeira, H. Guerreiro

Centro Hospitalar do Algarve, Faro, Portugal

P418

Ulcerative colitis and end-stage liver disease in children with primary sclerosing cholangitis

Authors:

P. Czubkowski*, M. Wozniak, J. Pawlowska, I. Jankowska, J. Kierkus

The Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

P419

Efficacy of vedolizumab in patients with inflammatory bowel disease and failure of anti-TNF-antibodies

Authors:

C. Höög*, M. Eberhardson, S. Almer

Karolinska Institute, Stockholm, Sweden

P420

Does vedolizumab change mural vascularisation in ulcerative colitis and is there a correlation with endoscopic findings?

Authors:

D. Klett*, D. Strobel, D. Wildner, R. Atreya, M. F. Neurath, R. S. Görtz

Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine I, Erlangen, Germany

P421

Skin side effects of biologic therapy and systemic drugs in patients with inflammatory bowel diseases

Authors:

K. Juzlova1, K. Koblova1, J. Herzogova1, M. Bortlik*2, D. Duricova2, M. Lukas2

12nd Faculty of Medicine, Charles University, Department of Dermatovenereology, Prague, Czech Republic, 2Charles University, IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic

P422

Risks and clinical features of active tuberculosis developed in patients with inflammatory bowel disease receiving anti-tumour necrosis factor therapy

Authors:

J. W. Lee, C. H. Choi*

Chung-Ang University College of Medicine, Internal Medicine, Seoul, South Korea

P423

Paediatric Crohn’s disease patients with refractory psoriasis treated with a combination of infliximab and ustekinumab

Authors:

C. Olbjørn*1, 2, J. B. Rove1, J. Jahnsen2, 3

1Akershus University Hospital, Department of Paediatric and Adolescent Medicine, Lørenskog, Norway, 2University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 3Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway

P424

Surgery for children with Crohn’s disease.

Authors:

M. Stefanowicz*1, H. Ismail1, G. Kowalewski1, A. Kowalski1, J. Kierkuś2, P. Kaliciński1

1Children’s Memorial Health Institute, Department of Paediatric Surgery and Organ Transplantations, Warszawa, Poland, 2Children’s Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warszawa, Poland

P425

Comparison of therapeutic choices in biologic experienced Crohn’s disease and ulcerative colitis patients in Europe: discontinuation rates because of disease improvements

Authors:

A. Franceschetti*1, A. Baskett2, H. McKenzie2

1Ipsos healthcare, London, United Kingdom, 2Ipsos Healthcare, London, United Kingdom

P426

Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn’s disease

Authors:

E. Zittan*1, 2, O. B. Kelly1, B. Kabakchiev1, G. C. Nguyen1, K. Croitoru1, A. H. Steinhart1, M. S. Silverberg1

1Mount Sinai Hospital, Zane Cohen Centre for Digestive Diseases; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Canada, 2Institute of Gastroenterology and Liver Diseases, Emek Medical Centre, Afula, Israel

P427

The real-life experience of vedolizumab efficacy and safety in Crohn’s disease: a prospective observational multicentre cohort study

Authors:

A. Amiot*1, J. C. Grimaud2, X. Treton3, J. Filippi4, B. Pariente5, L. Peyrin-Biroulet6, A. Noureille7, A. Buisson8, F. Carbonnel9, A. Bourrier10, S. Nancey11, X. Roblin12, P. Marteau13, R. Altwegg14, J. Moreau15, A. Aubourg16, G. Savoye17, A. L. Pelletier18, M. Fumery19, B. Bonaz20, Y. Bouhnik3

1Henri Mondor Hospital, Gastroenterology, Creteil, France, 2Hospital Nord, Department of Gastroenterology and Hepatology, Marseille, France, 3APHP Beaujon, Department of Gastroenterology, Clichy, France, 4Archet 2 Hospital, Department of Gastroenterology, Nice, France, 5CHRU Lille, Department of Gastroenterology, Lille, France, 6CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France, 7CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, 8CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France, 9CHU Bicêtre, Department of Gastroenterology, Le Kremlin-Bicêtre, France, 10APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France, 11Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France, 12University of Saint Etienne, Department of Gastroenterology, Saint Etienne, France, 13Hospital Lariboisière, Department of Gastroenterology, Paris, France, 14CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France, 15CHU de Toulouse Hospital de Rangueil, Department of Gastroenterology, Toulouse, France, 16Chu Tours, Department of Gastroenterology and Hepatology, Tours, France, 17CHU Rouen, Department of Gastroenterology, Rouen, France, 18Hospital Bichat Claude Bernard, Department of Gastroenterology, Paris, France, 19Amiens University Hospital, Department of Gastroenterology, Amiens, France, 20Grenoble, gastroenterologie, Grenoble, France

P428

Tofacitinib pharmacokinetics and durability of drug exposure in moderate-to-severe Crohn’s disease patients in Phase 2 induction and maintenance studies

Authors:

A. Mukherjee1, C. Deng2, R. Xie2, S.W. Martin3, G. Chan4, M. Moscariello4, W. Niezychowski4, E. Maller*4

1Pfizer Inc, Groton, United States, 2Pfizer Inc, Shanghai, China, 3Pfizer Inc, Cambridge, United States, 4Pfizer Inc, Collegeville, Pennsylvania, United States

P429

The effects of psychiatric treatment in patients with inflammatory bowel disease: a prospective study

Authors:

O. Yanartas1, H. c. T. Kanı2, E. Bicakci3, Y. Bez1, M. Banzragch3, Z. Senkal1, I. Kilic4, O. Atug3, K. Kuscu1, N. Imeryuz3, H. Akin*3

1Marmara University, Psychiatry, Istanbul, Turkey, 2Marmara University, Internal Medicine, Istanbul, Turkey, 3Marmara University, Gastroenterology, Istanbul, Turkey, 4Marmara University, Medical Student, Istanbul, Turkey

P430

Prognostic significance of serial faecal calprotectin in inflammatory bowel disease

Authors:

Y. Zhulina1, Y. Cao2, K. Amcoff3, M. Carlson3, C. Tysk1, J. Halfvarson*1

1Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, 2Örebro University, Clinical Epidemiology and Biostatistics, Faculty of Medicine and Health, Örebro, Sweden, 3Uppsala University, Department of Medical sciences, Gastroenterology Research Group, Uppsala, Sweden